Pemigatinib — Drug Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

6 Recruiting

4 Completed trials

9 Sponsors

12 Countries

Phase II

Phase III: 1 Phase II: 10

Oversight events:

1 serious breach 2 urgent safety measures across 2 trials

View oversight register →

Indications tested

Liposarcoma metastatic 1 Cholangiocarcinoma 1 Endometrial cancer metastatic 1 Endometrial cancer 1 Dedifferentiated liposarcoma 1

Sponsors using this IMP

Incyte Corp. 3 Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH 1 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 1 HUS-Yhtymae 1 Oslo University Hospital HF 1 Region Hovedstaden 1 Region Skane 1 Rigshospitalet 1 Unicancer 1

All trials

11 total

Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer Pending

2025-522431-34-00 Phase II 1 country Region Hovedstaden
Clinical trial evaluating the efficacy of pemigatinib for the treatment of patients with solid tumours with an alteration of the gene FGFR Recruiting

2024-512729-10-00 Phase II 1 country Unicancer
FINPROVE - The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Recruiting

2024-517478-68-01 Phase II 1 country HUS-Yhtymae
PERELI - A phase 2, open label study of PEmigatinib and REtifanlimab in advanced dedifferentiated Liposarcoma Recruiting

2022-501993-21-00 Phase II 3 countries Region Skane
Improving public cancer care by implementing precision medicine in Norway Recruiting

2023-507894-16-00 Phase II 1 country Oslo University Hospital HF
ProTarget - A Danish Nationwide Clinical Trial on Targeted Anti‐Cancer Treatment based on Genomic Profiling Recruiting

2023-510527-29-00 Phase II 1 country Rigshospitalet
DRUP trial Recruiting

2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cance… Ended

2022-502600-79-00 Phase II 4 countries Incyte Corp.
PEARLDIFER - A Phase II study of pemigatinib after curative local therapy in locally advanced intrahepatic cholangiocarcinoma (iCCA) harbori… Ended

2024-512018-16-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in… Ended

2023-503406-36-00 Phase II 1 country Incyte Corp.
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabin… Ended

2024-513513-12-00 Phase III 8 countries Incyte Corp.

Showing 1–11 of 11 trials

← All drugs A–Z